Metzger J F, Lewis G E
Rev Infect Dis. 1979 Jul-Aug;1(4):689-92. doi: 10.1093/clinids/1.4.689.
The need for a human-derived immune globulin to replace the equine antitoxins currently used in the treatment of botulism is well recognized. A small group of individuals who had received multiple immunizations with pentavalent botulinal toxoid were plasmapheresed for the purpose of collecting a botulism-immune plasma of human origin to be fractionated for the production of immune globulin. Human-derived immune globulin will offer the advantage over equine antitoxins of not inducing reactions to foreign protein and of having a prolonged effective half-life.
人们已经充分认识到需要一种人源免疫球蛋白来替代目前用于治疗肉毒中毒的马抗毒素。一小群接受过五价肉毒类毒素多次免疫的个体接受了血浆置换，目的是收集人源肉毒中毒免疫血浆，用于分离制备免疫球蛋白。人源免疫球蛋白相对于马抗毒素具有优势，它不会引发对外源蛋白的反应，并且有效半衰期更长。
